Sonrotoclax - BeiGene
Alternative Names: BGB-11417Latest Information Update: 29 Nov 2024
Price :
$50 *
At a glance
- Originator BeiGene
- Developer Amgen; BeiGene
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic lymphocytic leukaemia
- Phase II Mantle-cell lymphoma; Multiple myeloma; Richter's syndrome; Waldenstrom's macroglobulinaemia
- Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
- No development reported B-cell lymphoma
Most Recent Events
- 20 Nov 2024 BeiGene plans a phase I/II trial for Chronic lymphocytic leukaemia (First-line therapy) (PO), in December 2024 (NCT06697184)
- 15 Oct 2024 BeiGene plans a phase II trial for Chronic lymphocytic leukaemia (Combination therapy, First-line therapy) (PO) in December 2024 (NCT06637501)
- 13 Sep 2024 Efficacy and adverse events data from a phase I/II trial in Acute myeloid leukemia presented at the 29th Congress of the European Haematology Association (EHA-2024)